Biopartnering
Apop’s breakthrough technologies are transforming our knowledge of complex cell stress mechanisms (apoptosis and autophagy) associated with serious diseases. Apop's first commercial product range is a pipeline of proprietary novel imaging reagents. All Apop products are based on our proprietary calcitonin receptor monoclonal antibody technology, CalRexin™ that targets a novel extracellular marker of these complex processes and backed by multiple scientific publications.
CalRexin™ imaging reagents are first-in-class products that deliver high-fidelity data to meet a growing demand for more effective tools to detect and monitor cell stress events such as autophagy and apoptosis. The dysregulation of these critical cellular pathways are associated with diseases such as neurodegeneration, cancer, and pathogenic infections. CalRexin™ imaging reagents are available in a range of monoclonal antibody: fluorophore conjugates to detect apoptosis (death) and autophagy in cells that are cultured.
CalRexin® imaging reagents
CalRexin™:pHrodo™ Red
CalRexin™:pHrodo™ Red is a first-in-class imaging reagent that identifies a novel marker of autophagy, namely activated calcitonin receptor. CalRexin™:pHrodo™ Red resists photobleaching and is extremely stable, properties that are essential for high throughput/content imaging of live cells over 24 hours at multiple timepoints.
Unlike alternatives, CalRexin™:pHrodo™ Red passes through sequential structures of the autophagy pathway from early endosomes to autolysosomes where it fluoresces brightly in the low pH environment, illuminating multiple components of the autophagic process, in real time. CalRexin™:pHrodo™ Red provides exceptional, high-fidelity data and is utilised for primary screening of autophagy-modulating compounds from small molecule libraries on high throughput/content platforms, invaluable for drug discovery.
CalRexin™:488, CalRexin™:568, CalRexin™:647, CalRexin™:680
Apop’s suite of proprietary CalRexin™ imaging reagents target the Calcitonin receptor, a novel marker of PCD. CalRexin™ imaging reagents can be readily incorporated into standard workflows such as flow cytometry, are able to identify sub-populations of stressed (dying) cells and provide exceptional image clarity of cells undergoing autophagy and apoptosis.
These are just two of the processes associated with PCD identified so far. CalRexin™ can be utilised for live cell assays and unlike alternatives, are stable without the spectre of false positives.
The Apop cell stress/PCD imaging product range is being followed by a range of emerging therapeutics, and diagnostics products that are under development:
Therapeutics and diagnostics - early stage
A therapeutic target (ADC/Antibody:immunotoxin) for treatment of one of the most recalcitrant cancers, Glioblastoma Multiforme is also currently under development with 2 globally recognized universities in Australia and Germany. The third platform technology for CalRexin is for sensitive imaging of PCD in patients and whole organisms , eg PET scanning.
